CAPRICOR THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 8, 2024.
| CAPRICOR THERAPEUTICS, INC. | |
| By: | /s/ Linda Marbán, Ph.D. |
| Linda Marbán, Ph.D. | |
| Chief Executive Officer |
KNOW ALL MEN BY THESE PRESENTS, that we, the undersigned officers and directors of Capricor Therapeutics, Inc., hereby severally constitute Linda Marbán, Ph.D. and Anthony J. Bergmann and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in our names and in our capacities as officers and directors to enable Capricor Therapeutics, Inc. to comply with the provisions of the Securities Exchange Act of 1934, and all requirements of the U.S. Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to any and all amendments hereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Linda Marbán, Ph.D. | Chief Executive Officer and Director | March 8, 2024 | ||
| Linda Marbán, Ph.D. | (Principal Executive Officer) | |||
| /s/ Anthony J. Bergmann | Chief Financial Officer | March 8, 2024 | ||
| Anthony J. Bergmann | (Principal Financial and Principal Accounting Officer) | |||
| /s/ Frank Litvack, M.D. | Executive Chairman and Director | March 8, 2024 | ||
| Frank Litvack, M.D. | ||||
| /s/ Earl M. Collier | Director | March 8, 2024 | ||
| Earl M. Collier | ||||
| /s/ David B. Musket | Director | March 8, 2024 | ||
| David B. Musket | ||||
| /s/ George W. Dunbar | Director | March 8, 2024 | ||
| George W. Dunbar | ||||
| /s/ Karimah Es Sabar | Director | March 8, 2024 | ||
| Karimah Es Sabar | ||||
| | | | | |
| /s/ Paul Auwaerter | Director | March 8, 2024 | ||
| Paul Auwaerter | ||||
| | | | | |
| /s/ Michael Kelliher | Director | March 8, 2024 | ||
| Michael Kelliher | ||||
| | | | | |
| /s/ Philip Gotwals | Director | March 8, 2024 | ||
| Philip Gotwals | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.